Guselkumab (Tremfya®) was launched in November 2018 in Japan and improves symptoms by inhibiting IL-23, which is involved in the maintenance and proliferation of helper T (Th) 17 cells involved in neutrophil activation and pustule formation in PPP. The gene discussed is IL23A; the disease is palmoplantar pustulosis.